Opendata, web and dolomites

HEMOSNOW

HEMOSNOW: A revolution in haemostatic technology to stop bleeding in delicate surgery and enhance patient recovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEMOSNOW project word cloud

Explore the words cloud of the HEMOSNOW project. It provides you a very rough idea of what is the project "HEMOSNOW" about.

biosurgery    conventional    vision    minimum    surgeons    people    haemostatic    2005    drainage    employ    stops    difficult    company    resorbable    surgeon    quantitatively    powder    ready    equip    formulations    specialises    day    formulation    lengthy    time    biom    errors    die    risk    wounds    stopping    spotgrade    postoperative    risks    million    generate    procedure    suitable    medical    size    founded    normal    lower    6minutes    feasible    haemostasis    42    commercialisation    pain    longer    always    patients    250    stay    revenue    biotech    faster    benefit    contributes    patented    542    stick    bleeding    haemostats    operative    hour    038    techniques    mechanism    healthcare    vessels    supplementing    obscured    delayed    stays    french    designed    preparation    hospitals    room    electrocautery    post    recovery    rapid    arrest    hemosnow    incurs    accumulated    excessive    accessible    554    instruments    reduce    collagen    surgical    tool    times    limits    transfusion    applicability    agents    blood    restricted    hospital    body    surgery   

Project "HEMOSNOW" data sheet

The following table provides information about the project.

Coordinator
BIOM'UP SA 

Organization address
address: 8, ALLEE IRENE JOLIOT CURIE
city: SAINT-PRIEST
postcode: 69800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.biomup.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOM'UP SA FR (SAINT-PRIEST) coordinator 50˙000.00

Map

 Project objective

Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMOSNOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMOSNOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More  

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More